Psychiatry Portfolio

The Supernus Pharmaceuticals psychiatry portfolio includes 2 product candidates for the treatment of ADHD or its coexisting conditions and 1 product candidate for depression. Each of these products is designed to bring important advancements to existing therapies.

SPN-810 (molindone hydrochloride)

SPN-810 is a novel treatment for impulsive aggression in patients with ADHD, with the potential to be the first product available to address this serious, unmet medical need.

Previously marketed in the United States to treat schizophrenia under the trade name Moban^®, molindone hydrochloride is unusual among antipsychotics in that it is less likely to be associated with weight gain.

In addition, the lower doses tested for the proposed indication of impulsive aggression may be better tolerated than the higher doses approved to treat schizophrenia.

These attributes make SPN-810 a potential attractive candidate for the effective treatment of impulsive aggression in patients with ADHD.

SPN-810 is in Phase IIb.

SPN-812

SPN-812 is a novel nonstimulant treatment for ADHD.

As a selective norepinephrine reuptake inhibitor, SPN-812 may be more effective and could have a better side-effect profile than other nonstimulant treatments for ADHD.

While the active ingredient in SPN-812 has an extensive safety record in Europe, where it has been marketed for many years as an antidepressant, SPN-812 could provide an additional option to the few nonstimulant therapies currently available.

SPN-812 completed a Phase IIa study with positive data.

SPN-809

SPN-809 is a novel once-daily norepinephrine reuptake inhibitor for the treatment of depression.

SPN-809 is based on the same active ingredient that is in SPN-812. An open Investigational New Drug (IND) application currently exists for SPN-809 as a treatment of depression. The active ingredient in SPN-809 has been approved and marketed for depression in Europe for many years.